Ovid Therapeutics Inc. Common Stock (OVID) Stock
NASDAQ · OVID
2.40
Fundamentals
Market cap
$468.71M
Price / Earnings ratio
-14.1x
Price / Sales ratio
307.8x
Price / Book ratio
2.3x
Return on assets
-19.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
NeutralOVIDAugust 18, 2026
Zacks Investment ResearchNeutral
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
OVID

Zacks Investment Research
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
NeutralOVIDAugust 13, 2026
Zacks Investment ResearchNeutral
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
OVID

Zacks Investment Research
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
NeutralOVIDAugust 5, 2026
Zacks Investment ResearchNeutral
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
OVID

The Motley Fool
Here's Why Ovid Therapeutics Stock Popped Higher Today
NeutralOVIDMarch 18, 2026
The Motley FoolNeutral
Here's Why Ovid Therapeutics Stock Popped Higher Today
OVID
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
9M6M3M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
181M120M60M0
Revenue to Profit
2025$7.3M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-17.4M
Net incomeEarnings
No data available
% positive news of 9 articles
published over the past 14 days
Latest news

Zacks Investment Research
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
NeutralOVIDAugust 18, 2026
Zacks Investment ResearchNeutral
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
OVID

Zacks Investment Research
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
NeutralOVIDAugust 13, 2026
Zacks Investment ResearchNeutral
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
OVID

Zacks Investment Research
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
NeutralOVIDAugust 5, 2026
Zacks Investment ResearchNeutral
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
OVID

The Motley Fool
Here's Why Ovid Therapeutics Stock Popped Higher Today
NeutralOVIDMarch 18, 2026
The Motley FoolNeutral
Here's Why Ovid Therapeutics Stock Popped Higher Today
OVID

Zacks Investment Research
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
NeutralOVIDMarch 18, 2026
Zacks Investment ResearchNeutral
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
OVID

Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
NeutralOVIDJune 17, 2024
BenzingaNeutral
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
OVID

Investors Business Daily
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
NeutralOVIDApril 14, 2023
Investors Business DailyNeutral
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
OVID

InvestorPlace
3 Biotech Stocks Under $10 to Add to Your Buy List
NeutralOVIDApril 26, 2022
InvestorPlaceNeutral
3 Biotech Stocks Under $10 to Add to Your Buy List
OVID

Benzinga
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
NeutralOVIDJanuary 3, 2022
BenzingaNeutral
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
OVID
About Ovid Therapeutics Inc. Common Stock
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
SectorHealthcare
IndustryBiotechnology
Employees23
CEOMs. Margaret Alexander
IPO DateMay 5, 2017
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder & Executive Chairman | 1953 |
| Ms. Margaret Alexander | CEO, President & Director | 1981 |
| Mr. Jeffrey A. Rona | Advisor | 1968 |
| Mr. Charles Ross Carter M.B.A., M.S. | CFO, Principal Financial Officer, Principal Accounting Officer & Secretary | 1967 |
| Dr. Zhong Zhong Ph.D. | Chief Scientific Officer | — |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development | 1975 |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research | — |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer | — |
| Ms. Victoria Fort | Chief Strategy Officer | — |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer | 1966 |
Fundamentals
Valuation
Market cap$468.71M
Price-to-sales ratio307.83
Price-to-book value2.32
Price-earnings ratio-14.10
Return on Equity-23.00%
Return on Sales-339.00%
Return on Assets-19.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-0.23
Income Statement
Average volume1,737,297
EBITDA$-22.79M
1 year high (52w)$3.11
1 year low (52w)$1.18
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$7.00
Est return
191.67%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +32.1 | +28.2 | -2.2 | +5.1 | -17.2 | +14.6 | -13.0 |



